Chester County News and Community Website
WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) application to expand Imfinzi into another form of bladder cancer has received FDA Priority Review after a Phase III trial showed the drug combination …
FDA Speeds Review of AstraZeneca Bladder Cancer Regimen Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. is seeking U.S. Food and Drug Administration approval for a redesigned late-stage development plan that could cut enrollment in its Teverelix advanced prostate cancer …
Medicus Seeks FDA Path to Cut Teverelix Trial by 60% Read More
NEWTOWN, PA — KVK-Tech Inc. completed a U.S. Food and Drug Administration inspection of its opioid risk-management compliance on Sept. 18 without receiving a Form FDA 483, indicating investigators recorded …
KVK-Tech Clears FDA Opioid Compliance Inspection Read More
WASHINGTON, D.C. — The U.S. Department of Agriculture is directing federally overseen agricultural checkoff programs to halt funding for certain environmental, social, and governance initiatives, immediately restricting how mandatory producer …
USDA Orders Checkoff Programs to End ESG-Focused Spending Read More
WASHINGTON, D.C. — The U.S. Department of Agriculture is targeting higher ethanol blending and fewer trade restrictions in markets from Mexico to Southeast Asia as it seeks to extend a …
USDA Targets New Markets After Record Ethanol Exports Read More
WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) received a revised Nov. 10 regulatory goal date for its preservative-free ketamine application after the U.S. Food and Drug Administration reclassified a …
NRx Gets Earlier FDA Goal Date for Ketamine Application Read More
WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) received U.S. Food and Drug Administration clearance to begin a Phase 1 trial of PRT13722, moving its experimental KAT6A-targeting breast cancer drug …
Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial Read More
WASHINGTON, D.C. — The U.S. Department of Energy selected four projects for $73 million in funding to establish domestic mining-technology test sites, seeking to move new extraction and processing systems …
DOE Directs $73 Million to Test New U.S. Mining Technology Read More WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) ETCAMAH (camizestrant) combination won accelerated U.S. approval for certain advanced breast cancer patients whose tumors develop an ESR1 mutation during first-line therapy, allowing treatment …
FDA Clears AstraZeneca Breast Cancer Regimen on Early Detection Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) received FDA authorization to begin an NDA-enabling Phase 2b study of SkinJect in patients with Gorlin Syndrome, advancing the company’s lead program …
FDA Clears Medicus SkinJect Study for Gorlin Syndrome Read More